EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine

Waldemar Rastawicki iD, Rafał Gierczyński, Aleksandra Anna Zasada iD

Viruses · 2023

DOI: 10.3390/v15040970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Waldemar Rastawicki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology and Biocontamination Control, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are limited reports concerning the levels of antibodies in IgG subclasses and the avidity of IgG, which is the functional strength with which an antibody binds to an antigen in serum samples obtained at different times after infection or vaccination. This study investigated the kinetics of antibody avidity and the IgG antibody response within IgG1-IgG4 subclasses in individuals vaccinated with the BNT162B2 mRNA vaccine and in COVID-19 patients. Serum samples were collected from individuals vaccinated with three doses of the BNT162B2 (Comirnaty, Pfizer/BioNTech) vaccine and from unvaccinated COVID-19 patients. This study revealed that IgG1 was a dominating subclass of IgG both in COVID-19 patients and in vaccinated individuals. The level of IgG4 and IgG avidity significantly increased 7 months after the first two doses of the vaccine and then again after the third dose. IgG2 and IgG3 levels were low in most individuals. Investigating IgG avidity and the dynamics of IgG subclasses is essential for understanding the mechanisms of protection against viral infections, including COVID-19, especially in the context of immunization with innovative mRNA vaccines and the possible future development and application of mRNA technology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19HumansAntibody AffinityKineticsImmunoglobulin GmRNA VaccinesVaccinationAntibodies, Viral

Stichwörter der Autor:innen

COVID-19 vaccineSARS-CoV-2antibodyvaccination

Substanzen

BNT162 VaccineImmunoglobulin GmRNA VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Bacteriology and Biocontamination Control, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
  • Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.

ORCID-Profile: Waldemar Rastawicki, Aleksandra Anna Zasada

Zitieren

APA

Rastawicki, W., Gierczyński, R., & Zasada, A. A. (2023). Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine. Viruses. https://doi.org/10.3390/v15040970

Vancouver

Rastawicki W, Gierczyński R, Zasada AA. Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine. Viruses. 2023. doi:10.3390/v15040970

BibTeX
@article{Rastawicki2023,
  author = {Rastawicki, Waldemar and Gierczyński, Rafał and Zasada, Aleksandra Anna},
  title = {Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15040970}
}
Kostenlos starten →